Osimertinib with Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Trial Identifier:	D5161R00055
Sponsor:	AstraZeneca
Start Date:	July 2024
Primary Completion Date:	February 2028
Study Completion Date:	February 2028
Condition:	Lung Cancer; Cancer - Other; Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Shanghai, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.